🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Allogene Therapeutics, Inc. ALLO R2K

Healthcare · Biotechnology · United States
https://allogene.com
Company Profile ↓
$1.90
+47.29% 1Y
Mkt Cap$655.79M
P/E-2.57
P/B1.62
52W High$3.06
52W Low$1.03
Book Value$1.14
EPS (TTM)$-0.74

Company Overview

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 14.6% per year over the last five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.29.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR -33.3%, profit CAGR 14.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-33.33%
1 Year:-100.00%

Compounded Profit Growth

5 Years:14.64%
1 Year:-

Stock Price Performance

1 Year:+47.29%
6 Months:+13.77%
3 Months:-16.67%
1 Month:+0.00%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 43% of range
$1.03 $3.06
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)41.13 · Neutral
Price Performance
1M+0.00%
3M-16.67%
6M+13.77%
1Y+47.29%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 14.6% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -33.3% CAGR over 5 years.
  • Trading 37.9% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-2.57
Industry PE
25.88
Forward P/E
-2.78
PEG Ratio
-
Book Value
$1.14
Price to Book
1.62
P/S
-
EV/EBITDA
-2.73
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-33.33%
Profit 5Y
14.64%
Revenue (YoY)
-100.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-49.51%
ROE
-52.32%
ROA
-25.97%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.18
EPS (TTM)
$-0.74

Balance Sheet & Liquidity

Debt/Equity
0.29
Quick Ratio
9.47
Current Ratio
9.65
Debt
$81.05M
Total Assets
$395.96M
Current Assets
$273.29M
Working Capital
$225.24M

Ownership

Promoter Holding
11.04%
Chg in Prom Hold
0.01%
FII / Inst Holding
53.66%
Chg in FII Hold
0.31%

Financial Snapshot

Enterprise Value
$655.79M
Total Revenue (TTM)
$0
EBITDA
$-175.70M
Free Cash Flow
$-69.94M
Operating Cash Flow
$-109.23M
Shares Outstanding
345.15M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALLO Allogene Therapeutics, Inc. R2K 1.90 -2.57 $655.79M 0.00% -49.51% -52.32% -33.33% 14.64%
2 LLY Eli Lilly and Company SPX 1,156.63 41.13 $1.03T 0.60% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 247.02 28.66 $594.63B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.11 119.08 $431.29B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 418.52 31.54 $380.08B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 123.61 34.82 $305.29B 2.82% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 168.37 26.10 $261.12B 1.87% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 535.29 29.40 $198.93B 0.35% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 358.32 24.92 $193.39B 2.80% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------00038.34M44.00K49.00K39.00K64.00K27.00K30.00K22.00K22.00K22.00K0--00000
Cost of Revenue -----------------------------
Gross Profit -----------------------------
Operating Expenses ------------------------65.19M54.44M44.90M42.40M46.09M
Operating Income -2.60M-135.01M-22.19M-33.05M-36.46M-45.96M-55.01M-64.58M-57.68M-63.16M-68.04M-33.20M-71.03M-77.67M-80.01M-76.62M-82.51M-99.09M-80.54M-63.00M-69.50M-71.43M---65.19M-54.44M-44.90M-42.40M-46.09M
EBITDA -------------------------56.48M-47.57M-37.96M-35.44M-39.44M
Interest Expense ------------------------150.00K268.00K344.00K313.00K300.00K
Pretax Income -------------------------59.73M-50.94M-41.40M-38.81M-42.61M
Tax Provision -----------------------------
Net Income -2.60M-134.90M-43.50M-30.51M-31.59M-41.24M-50.73M-61.03M-54.48M-60.97M-66.20M-33.02M-70.94M-78.19M-78.61M-80.29M-84.24M-99.97M-79.23M-62.29M-65.00M-66.36M---59.73M-50.94M-41.40M-38.81M-42.61M
Diluted EPS ----------0.53-0.52-0.25-0.53-0.57-0.56-0.56-0.59-0.69-0.54-0.37-0.38-0.35---0.28-0.23-0.19-0.17-0.18
R&D Expense -122.49M10.87M-23.40M31.77M39.99M-42.04M47.30M51.42M55.18M52.29M58.72M60.16M57.17M63.64M80.24M62.04M45.98M52.26M50.35M44.71M-50.20M40.16M31.16M-32.00M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -00-156.00K95.00K22.00K0
Cost of Revenue --------
Gross Profit --------
Operating Expenses ----335.69M314.59M257.50M206.93M
Operating Income -192.84M-202.01M-258.24M--335.54M-314.49M-257.48M-206.93M
EBITDA -----321.24M-313.07M-243.33M-177.45M
Interest Expense -----0181.00K1.07M
Pretax Income -----340.41M-327.26M-257.15M-190.89M
Tax Provision ---0-0443.00K0
Net Income -211.50M-184.59M-250.22M--340.41M-327.26M-257.59M-190.89M
Diluted EPS --1.83-2.08--2.32-2.09-1.32-0.87
R&D Expense 151.86M144.53M192.99M220.18M256.39M242.91M192.30M150.15M

Balance Sheet (Annual)

Figures in USD.

Metric Nov 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Dec 2024Dec 2025
Total Assets --773.86M717.80M1.23B-978.09M955.62M894.48M821.58M750.13M773.01M713.41M642.84M548.71M415.90M
Current Assets ---------528.82M---459.12M303.39M257.75M
Cash & Equivalents --92.43M175.13M183.35M-84.51M96.04M74.36M61.90M109.93M154.76M69.25M83.16M75.22M51.69M
Inventory ----------------
Receivables ----------------
Total Liabilities -2.00K70.69M88.78M148.21M-112.82M149.14M151.08M154.70M158.12M151.60M132.78M130.60M126.53M123.36M
Current Liabilities -2.00K29.46M33.08M94.32M-36.62M44.18M48.08M53.73M59.40M54.58M37.49M37.08M35.52M32.51M
Long Term Debt ----------------
Total Debt ---------101.12M---95.12M90.76M83.25M
Total Equity 0-2.00K703.16M629.02M1.01B-865.27M806.48M743.40M666.88M592.01M621.41M580.63M512.23M422.18M292.54M
Shares Outstanding ---------144.44M---168.64M212.21M229.41M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -44.65M-137.35M-115.09M--220.52M-237.73M-200.30M-149.25M
Investing Cash Flow -632.80M164.08M-505.12M-106.16M163.29M75.69M95.56M
Financing Cash Flow 771.18M58.96M633.59M-2.95M95.69M116.67M30.16M
Capital Expenditure -3.23M-50.79M-65.96M--5.19M-1.52M-694.00K-386.00K
Free Cash Flow -47.89M-188.14M-181.05M--225.71M-239.25M-200.99M-149.63M
Net Change in Cash -----111.41M21.25M-7.94M-23.53M

Ratios (Annual)

Figures in %.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------
Operating Margin % -----215,087.2%-331,044.2%-1,170,372.7%-
Net Margin % -----218,214.1%-344,489.5%-1,170,863.6%-
ROE % -30.1%-29.3%-24.7%--51.0%-63.9%-61.0%-65.3%
ROCE % -25.9%-29.5%-22.8%--43.7%-51.9%-50.2%-54.0%

Shareholding Pattern

Insiders
11.04%
Institutions
53.66%
Public Float
60.32%

Top Institutional Holders

#Holder% HeldSharesValue
1 Pfizer Inc 6.38% 22.03M $40.76M
2 Blackrock Inc. 5.53% 19.09M $35.32M
3 TPG GP A, LLC 5.42% 18.72M $34.63M
4 State Street Corporation 2.51% 8.66M $16.02M
5 Primecap Management Company 2.43% 8.38M $15.50M
6 Vanguard Capital Management LLC 2.01% 6.92M $12.80M
7 Citadel Advisors Llc 1.97% 6.79M $12.57M
8 Price (T.Rowe) Associates Inc 1.56% 5.38M $9.95M
9 Two Sigma Investments, LP 1.56% 5.38M $9.94M
10 Geode Capital Management, LLC 1.19% 4.12M $7.63M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALLO

Yahoo Finance Wed, 15 Jul 2026

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in this Cohort with All R…

Yahoo Finance Fri, 10 Jul 2026

Kyverna Therapeutics Sinks 13%: Here’s Why

A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or the start of a painful unwind.…

Yahoo Finance Sun, 28 Jun 2026

Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions

Allogene Therapeutics is back in focus as its fair value estimate has been reset to US$8.49 from US$7.47, alongside a mix of price target moves across the Street. Some analysts have raised targets by US$2 to US$4 after the ALPHA3 trial upda…

Yahoo Finance Wed, 17 Jun 2026

How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the small-cap stocks with potential to rise 1000 percent. The company’s 2026 setup now rests on whether it can turn its off-the-shelf CAR T platform into clinical evidence across both canc…

Yahoo Finance Fri, 12 Jun 2026

Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo Finance Sun, 07 Jun 2026

Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the top penny stocks to buy in investors’ stock portfolio. On May 13, Allogene Therapeutics, Inc. (NASDAQ:ALLO) reiterated positive interim results in the ALPHA3 trial of cemacabtagene ans…

ALLO — Frequently Asked Questions

What is the current share price of Allogene Therapeutics, Inc. (ALLO)?

As of 2026-07-15 16:51 PDT, Allogene Therapeutics, Inc. (ALLO) trades at $1.90 on NasdaqGS. Its 52-week range is $1.03 to $3.06.

What is the market capitalisation of ALLO?

Allogene Therapeutics, Inc. (ALLO) has a market capitalisation of $655.79M on NasdaqGS.

What is the P/E ratio of ALLO?

ALLO trades at a trailing price-to-earnings (P/E) ratio of -2.57. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.62.

What is the return on equity (ROE) of ALLO?

ALLO has a return on equity (ROE) of -52.32%. Its return on capital employed (ROCE) is -49.51%.

Is ALLO a good stock to buy?

This page provides a data-driven analysis of Allogene Therapeutics, Inc. (ALLO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space